vs
Side-by-side financial comparison of CuriosityStream Inc. (CURI) and Journey Medical Corp (DERM). Click either name above to swap in a different company.
CuriosityStream Inc. is the larger business by last-quarter revenue ($19.2M vs $16.1M, roughly 1.2× Journey Medical Corp). Journey Medical Corp runs the higher net margin — -7.8% vs -19.7%, a 12.0% gap on every dollar of revenue. On growth, CuriosityStream Inc. posted the faster year-over-year revenue change (35.8% vs 27.3%). Over the past eight quarters, CuriosityStream Inc.'s revenue compounded faster (26.5% CAGR vs 11.0%).
Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
CURI vs DERM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.2M | $16.1M |
| Net Profit | $-3.8M | $-1.2M |
| Gross Margin | — | — |
| Operating Margin | -17.6% | -2.8% |
| Net Margin | -19.7% | -7.8% |
| Revenue YoY | 35.8% | 27.3% |
| Net Profit YoY | -34.6% | -182.0% |
| EPS (diluted) | $-0.07 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $19.2M | $16.1M | ||
| Q3 25 | $18.4M | $17.0M | ||
| Q2 25 | $19.0M | $15.0M | ||
| Q1 25 | $15.1M | $13.1M | ||
| Q4 24 | $14.1M | $12.6M | ||
| Q3 24 | $12.6M | $14.6M | ||
| Q2 24 | $12.4M | $14.9M | ||
| Q1 24 | $12.0M | $13.0M |
| Q4 25 | $-3.8M | $-1.2M | ||
| Q3 25 | $-3.7M | $-2.3M | ||
| Q2 25 | $784.0K | $-3.8M | ||
| Q1 25 | $319.0K | $-4.1M | ||
| Q4 24 | $-2.8M | $1.5M | ||
| Q3 24 | $-3.1M | $-2.4M | ||
| Q2 24 | $-2.0M | $-3.4M | ||
| Q1 24 | $-5.0M | $-10.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 82.3% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 56.0% | ||
| Q1 24 | — | 47.7% |
| Q4 25 | -17.6% | -2.8% | ||
| Q3 25 | -24.5% | -9.0% | ||
| Q2 25 | 2.5% | -19.2% | ||
| Q1 25 | 0.5% | -25.3% | ||
| Q4 24 | -27.4% | 17.7% | ||
| Q3 24 | -25.8% | -19.8% | ||
| Q2 24 | -20.6% | -19.7% | ||
| Q1 24 | -30.4% | -77.4% |
| Q4 25 | -19.7% | -7.8% | ||
| Q3 25 | -20.4% | -13.6% | ||
| Q2 25 | 4.1% | -25.3% | ||
| Q1 25 | 2.1% | -31.0% | ||
| Q4 24 | -19.9% | 12.1% | ||
| Q3 24 | -24.3% | -16.3% | ||
| Q2 24 | -16.4% | -22.6% | ||
| Q1 24 | -42.0% | -80.1% |
| Q4 25 | $-0.07 | $-0.04 | ||
| Q3 25 | $-0.06 | $-0.09 | ||
| Q2 25 | $0.01 | $-0.16 | ||
| Q1 25 | $0.01 | $-0.18 | ||
| Q4 24 | $-0.05 | $0.10 | ||
| Q3 24 | $-0.06 | $-0.12 | ||
| Q2 24 | $-0.04 | $-0.17 | ||
| Q1 24 | $-0.09 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.3M | $24.1M |
| Total DebtLower is stronger | — | $25.3M |
| Stockholders' EquityBook value | $41.5M | $31.9M |
| Total Assets | $75.7M | $94.6M |
| Debt / EquityLower = less leverage | — | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.3M | $24.1M | ||
| Q3 25 | $27.8M | $24.9M | ||
| Q2 25 | $28.1M | $20.3M | ||
| Q1 25 | $33.4M | $21.1M | ||
| Q4 24 | $32.1M | $20.3M | ||
| Q3 24 | $33.2M | $22.5M | ||
| Q2 24 | $39.5M | $23.9M | ||
| Q1 24 | $38.8M | $24.1M |
| Q4 25 | — | $25.3M | ||
| Q3 25 | — | $25.2M | ||
| Q2 25 | — | $25.1M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | — | $24.9M | ||
| Q3 24 | — | $19.8M | ||
| Q2 24 | — | $19.7M | ||
| Q1 24 | — | $14.7M |
| Q4 25 | $41.5M | $31.9M | ||
| Q3 25 | $47.2M | $25.9M | ||
| Q2 25 | $49.8M | $19.2M | ||
| Q1 25 | $58.1M | $21.5M | ||
| Q4 24 | $57.8M | $20.1M | ||
| Q3 24 | $62.2M | $10.9M | ||
| Q2 24 | $64.8M | $11.3M | ||
| Q1 24 | $67.0M | $13.0M |
| Q4 25 | $75.7M | $94.6M | ||
| Q3 25 | $74.7M | $85.2M | ||
| Q2 25 | $78.7M | $81.2M | ||
| Q1 25 | $85.3M | $85.0M | ||
| Q4 24 | $86.2M | $80.2M | ||
| Q3 24 | $87.6M | $64.0M | ||
| Q2 24 | $90.9M | $65.2M | ||
| Q1 24 | $94.6M | $66.6M |
| Q4 25 | — | 0.79× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 1.30× | ||
| Q1 25 | — | 1.16× | ||
| Q4 24 | — | 1.24× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | 1.13× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.0M | $-6.3M |
| Free Cash FlowOCF − Capex | $3.9M | — |
| FCF MarginFCF / Revenue | 20.5% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.0M | $-6.3M | ||
| Q3 25 | $4.4M | $-2.4M | ||
| Q2 25 | $2.8M | $-942.0K | ||
| Q1 25 | $1.9M | $-2.8M | ||
| Q4 24 | $3.0M | $2.2M | ||
| Q3 24 | $2.3M | $-1.2M | ||
| Q2 24 | $2.2M | $-5.2M | ||
| Q1 24 | $666.0K | $-5.0M |
| Q4 25 | $3.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $1.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 20.5% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 12.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.56× | — | ||
| Q1 25 | 6.03× | — | ||
| Q4 24 | — | 1.46× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CURI
Segment breakdown not available.
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
